Revance Therapeutics Inc. (RVNC) CEO Sells $215,040.00 in Stock
Revance Therapeutics Inc. (NASDAQ:RVNC) CEO L Daniel Browne sold 12,000 shares of the company’s stock in a transaction on Friday, November 25th. The shares were sold at an average price of $17.92, for a total value of $215,040.00. Following the transaction, the chief executive officer now directly owns 208,449 shares in the company, valued at $3,735,406.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
L Daniel Browne also recently made the following trade(s):
- On Wednesday, October 26th, L Daniel Browne sold 12,000 shares of Revance Therapeutics stock. The shares were sold at an average price of $14.85, for a total value of $178,200.00.
Shares of Revance Therapeutics Inc. (NASDAQ:RVNC) opened at 16.75 on Thursday. Revance Therapeutics Inc. has a 12 month low of $12.35 and a 12 month high of $40.40. The firm has a 50-day moving average price of $15.79 and a 200-day moving average price of $15.46. The stock’s market cap is $477.63 million.
Revance Therapeutics (NASDAQ:RVNC) last announced its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.89) by $0.25. Revance Therapeutics had a negative return on equity of 37.31% and a negative net margin of 28,187.33%. During the same period in the prior year, the firm posted ($0.81) EPS. Equities analysts forecast that Revance Therapeutics Inc. will post ($3.21) EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Revance Therapeutics Inc. (RVNC) CEO Sells $215,040.00 in Stock” was posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be accessed at http://www.dailypolitical.com/2016/12/01/revance-therapeutics-inc-rvnc-ceo-sells-215040-00-in-stock.html.
A number of research firms recently commented on RVNC. Aegis began coverage on Revance Therapeutics in a research report on Tuesday. They set a “buy” rating and a $28.00 price objective for the company. Zacks Investment Research cut Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 10th. Finally, Brean Capital reiterated a “hold” rating on shares of Revance Therapeutics in a research report on Friday, August 5th. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $35.17.
Hedge funds have recently bought and sold shares of the company. Rothschild Asset Management Inc. acquired a new stake in Revance Therapeutics during the second quarter worth $143,000. Janney Montgomery Scott LLC acquired a new stake in Revance Therapeutics during the second quarter worth $288,000. Bank of New York Mellon Corp boosted its stake in Revance Therapeutics by 7.8% in the second quarter. Bank of New York Mellon Corp now owns 2,118,558 shares of the biopharmaceutical company’s stock worth $28,812,000 after buying an additional 152,383 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Revance Therapeutics by 9.9% in the second quarter. JPMorgan Chase & Co. now owns 3,327,022 shares of the biopharmaceutical company’s stock worth $45,247,000 after buying an additional 298,448 shares during the last quarter. Finally, Suffolk Capital Management LLC boosted its stake in Revance Therapeutics by 64.6% in the second quarter. Suffolk Capital Management LLC now owns 158,812 shares of the biopharmaceutical company’s stock worth $2,160,000 after buying an additional 62,341 shares during the last quarter.
About Revance Therapeutics
Revance Therapeutics, Inc is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable.
Receive News & Ratings for Revance Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.